mcbain to post.ppt · microflora Facultative anaerobes (Streprococci Actinomycetes etc....

15
6/21/2014 1 Oral Health Applications for Probiotics Andrew McBain Biofilm Research Group Manchester Pharmacy School University of Manchester 2 Overview • Oral microbiology introduction • Dental probiotics and “replacement therapy”

Transcript of mcbain to post.ppt · microflora Facultative anaerobes (Streprococci Actinomycetes etc....

Page 1: mcbain to post.ppt · microflora Facultative anaerobes (Streprococci Actinomycetes etc. Predominantly Gram -ve ... Microsoft PowerPoint - mcbain to post.ppt [Compatibility Mode] Author:

6/21/2014

1

Oral Health Applications for Probiotics

Andrew McBainBiofilm Research GroupManchester Pharmacy SchoolUniversity of Manchester

2

Overview

• Oral microbiology introduction

• Dental probiotics and “replacement therapy”

Page 2: mcbain to post.ppt · microflora Facultative anaerobes (Streprococci Actinomycetes etc. Predominantly Gram -ve ... Microsoft PowerPoint - mcbain to post.ppt [Compatibility Mode] Author:

6/21/2014

2

3

Distribution

Accumulation at: • Gingival margins

(gingivitis / periodontal disease)

• Tooth fissures (dental caries)

•Tongue and other mucosal surfaces

Density

•Saliva: c. 108 per ml

•Plaque c. 1011 per gram

The Oral Microbiota

4

Taxonomy

Aas JA et al. (2005) Defining the normal bacterial flora of the oral cavity. J Clin Microbiol. 2005 Nov;43(11):5721-32.

c. 700* oral species. 50% currently uncultivated

Firmicutes (e.g. streptococci)Actinobacteria (e.g. Actinomyces)Proteobacteria (e.g. Neisseria)Bacteroidetes (e.g. Porphyromonas)Fusobacteria (e.g. Fusobacterium)TM7 phylum (so far uncultivated)

c. 50% culturability

Page 3: mcbain to post.ppt · microflora Facultative anaerobes (Streprococci Actinomycetes etc. Predominantly Gram -ve ... Microsoft PowerPoint - mcbain to post.ppt [Compatibility Mode] Author:

6/21/2014

3

Planktonic bacteria

3. Biofilm dispersion

2.Plaque development1. Colonisation

Coaggregation

Coadhesion

Aggregation

, Plaque matrix; , Tooth surface , Bacteria.

How does plaque form?

6

The Oral Microbiota and Disease Processes

•The specific plaque hypothesis- specific pathogens

•The non-specific plaque hypothesis- all plaque is bad

•The ecological plaque hypothesis- change in environment -> adverse change

in microbiota -> disease

Page 4: mcbain to post.ppt · microflora Facultative anaerobes (Streprococci Actinomycetes etc. Predominantly Gram -ve ... Microsoft PowerPoint - mcbain to post.ppt [Compatibility Mode] Author:

6/21/2014

4

The ecological plaque hypothesisfor periodontal disease

GIN

GIV

AL

HE

ALT

HG

ING

IVIT

IS

INFLAMMATORYRESPONSE

ENVIRONMENTALCHANGE

ECOLOGICAL SHIFT

Plaquereduction

Plaqueaccumulation

Reduced inflammation

Increasedinflammation

Low GCF flowHigher oxygen

High GCF flowLower oxygen

PredominantlyGram +ve microflora

Facultative anaerobes

(StreprococciActinomycetes

etc.

PredominantlyGram -ve microfloraObligate

anaerobes

(Eubacterium Porthyromonas

Fusobacteriaetc.)

Philip Marsh

The ecological plaque hypothesisfor dental caries

HE

ALT

HC

arie

s

ENVIRONMENTAL SHIFT

DISEASE

Sugar intake

Acid production

Neutral pH

Low pH

High:Strep. Gordonii

Strep. OralisStrep. Mitis

A. naeslundii

Increased:

Strep. MutansLactobacilli

Bifidobacteria

Enamel health

Increased caries risk

Stress ECOLOGICAL SHIFT

Philip Marsh

Page 5: mcbain to post.ppt · microflora Facultative anaerobes (Streprococci Actinomycetes etc. Predominantly Gram -ve ... Microsoft PowerPoint - mcbain to post.ppt [Compatibility Mode] Author:

6/21/2014

5

9

The Oral Systemic Interface

• Purported relationships between periodontal disease and heart disease

• Maternal oral health and premature birth

• Oral health and bacteraemia

• Oral bacterial involvement in device-related infections.

10

Traditional managementDental hygiene

(Cleaning and antimicrobials)

Page 6: mcbain to post.ppt · microflora Facultative anaerobes (Streprococci Actinomycetes etc. Predominantly Gram -ve ... Microsoft PowerPoint - mcbain to post.ppt [Compatibility Mode] Author:

6/21/2014

6

11

11

Plaque and antimicrobials

Biofilm bacteria are 50-1000 x less susceptible to antibiotics and biocides than are planktonic bacteria

McBain, 2009

[Antimicrobials] [Oxygen][Nutrients]

“Bulk” phase

, Persister cells

Taxonomically distinct cell

clusters

Phenotypically distinct cell

clusters

Plaque recalitrance…

Page 7: mcbain to post.ppt · microflora Facultative anaerobes (Streprococci Actinomycetes etc. Predominantly Gram -ve ... Microsoft PowerPoint - mcbain to post.ppt [Compatibility Mode] Author:

6/21/2014

7

13

Viability Profiling of Streptococcus mutans Biofilms

Green= liveRed= dead

14

“Replacement therapy”applied directly to a site with the intention of combating or preventing an infection.

“Probiotics”delivered orally and have been associated with a wide range of claimed localised and systemic beneficial effects, proven or otherwise.

(prebiotic equivalents include urea and arginine)

Alternative approaches

Page 8: mcbain to post.ppt · microflora Facultative anaerobes (Streprococci Actinomycetes etc. Predominantly Gram -ve ... Microsoft PowerPoint - mcbain to post.ppt [Compatibility Mode] Author:

6/21/2014

8

15

Replacement therapy for the prevention of caries- a caries “vaccine”

Jeffrey Hillman originally at the Forsyth Dental Center, Boston

A key concept in this is the involvement of Streptococcus mutans in cariogenesis.

Replacement therapy for caries involves the use of mutants that do not produce lactic acid

From the press, “Oragenics, Jeff’s company, has patented a simple swab of bacteria that when wiped across a set of teeth will grant a lifetime of protection from tooth decay…”

16

Replacement TherapyEvidence?

Evidence from rat studies for both caries and periodontal disease.

Anecdotal evidence that Prof. Hillman and four colleagues have remained colonised by the ‘effector strains’ for over 20 years…

Regulatory problems with using engineered mutans strains in humans, Now focusing on natural mutans and S. rattus.

Page 9: mcbain to post.ppt · microflora Facultative anaerobes (Streprococci Actinomycetes etc. Predominantly Gram -ve ... Microsoft PowerPoint - mcbain to post.ppt [Compatibility Mode] Author:

6/21/2014

9

17

Dental Probiotics

Mainly lactobacilli (esp. L. reuteri)– Classed as safe (GRAS) by the FDA

Sporadic reports in the literature back to around 1954

Lactobacilli are lactic acid bacteria and lactic acid causes caries? Is there a conflict?

18

Caglar et al. 2006 Administered Lactobacillus reuteri ATCC 55730 or placebo once

daily to healthy young adults (120 in total) in four groups of 30 volunteers.

Group A drank 200ml of water containing a probiotic through a straw; Group B 200ml placebo water;

Group C sucked probiotic tablet and Group D sucked placebo tables.

Consumption of the probiotics via the tablet route resulted in highly significant decreases in S. mutans counts.

Significant decreases in mutans also occurred for individuals who used the straw.

The authors postulated that the lowering of S. mutans might occur by a systemic mechanism rather than direct interaction between probiotic and S. mutans.

Page 10: mcbain to post.ppt · microflora Facultative anaerobes (Streprococci Actinomycetes etc. Predominantly Gram -ve ... Microsoft PowerPoint - mcbain to post.ppt [Compatibility Mode] Author:

6/21/2014

10

19

Krasse et al. 2006

Administered two different Lactobacillus reuteri strains of human origin, or a placebo to 59 patients with moderate to severe gingivitis in Sweden.

Improvements (decreases in gingival indexes)were reported for the probiotic and control groups which were more significant for the probiotic group (both Lactobacillus strains). Interestingly, one of the lactobacillus strains appeared to be better clinically than the others.

20

Iniesta et al. 2012• Forty gingivitis subjects over 8 weeks administration of a daily tablet,

containing Lactobacillus reuteri or placebo.

• There were no significant changes between and within the groups in the clinical variables.

• In saliva, total anaerobic counts after 4 weeks and counts of Prevotella intermedia after 8 weeks, showed significant reductions in the test group.

• In subgingival samples, significant reductions were observed for P. gingivalis counts. L. reuteri ATCC-PTA-5289 was more frequently detected than L. reuteri DSM-17938 by PCR.

• The effect of L. reuteri administered in tablets resulted in a reduction in the number of selected periodontal pathogens in the subgingival microbiota, but without an associated clinical impact.

Page 11: mcbain to post.ppt · microflora Facultative anaerobes (Streprococci Actinomycetes etc. Predominantly Gram -ve ... Microsoft PowerPoint - mcbain to post.ppt [Compatibility Mode] Author:

6/21/2014

11

21

Sunstar GUM

• The lozenges are stated to contain at least 200 million active viable Lactobacillus reuteri “ProdentisTM” (a patented mixture of equal amounts of L. reuteri ATCC 55730 and L. reuteri ATCC PTA 5289)

22

• GRAS (generally regarded as safe)- FDA

• Easy to scale up

• Palatable

• Antagonistic to pathogens?

• Immunomodulation?

• Efficacy?

• But is acidogenesis an issue?

Why lactobacilli as dentalprobiotics?

Page 12: mcbain to post.ppt · microflora Facultative anaerobes (Streprococci Actinomycetes etc. Predominantly Gram -ve ... Microsoft PowerPoint - mcbain to post.ppt [Compatibility Mode] Author:

6/21/2014

12

23

Keller and Twetman, 2012,

24

Preclinical testing of L. reuteri in oral microbiotas

Page 13: mcbain to post.ppt · microflora Facultative anaerobes (Streprococci Actinomycetes etc. Predominantly Gram -ve ... Microsoft PowerPoint - mcbain to post.ppt [Compatibility Mode] Author:

6/21/2014

13

25

Facultative anaerobes

Pre-dosing Dosing Post-dosing

2

3

4

5

6

7

8Total anaerobes

Pre-dosing Dosing Post-dosing

2

3

4

5

6

7

8Gram -negative anaerobes

Pre-dosing Dosing Post-dosing

Log1

0 cf

u.m

m-2

2

3

4

5

6

7

8

Total streptococci

Pre-dosing Dosing Post-dosing

2

3

4

5

6

7

8Total lactobacilli

Pre-dosing Dosing Post-dosing

2

3

4

5

6

7

8Lactobacillus reuteri

Pre-dosing Dosing Post-dosing

2

3

4

5

6

7

8

Log1

0 cf

u.m

m-2

Mature plaques

26

Nascent plaques

Total anaerobes

6 5 5 6 6

2

3

4

5

6

7

8

Log

10C

FU

.mm

-2L

og1

0C

FU

.mm

-2

* *

Gram-negative anaerobes

2

3

4

5

6

7

8

**

Total streptococci

2

3

4

5

6

7

8

*

Total aerobes

2

3

4

5

6

7

8

*

Total lactobacilli

2

3

4

5

6

7

8

*

*

Control PT

LRPT

LRBF

ControlBF

Control PT

LRPT

LRBF

ControlBF

Control PT

LRPT

LRBF

ControlBF

Page 14: mcbain to post.ppt · microflora Facultative anaerobes (Streprococci Actinomycetes etc. Predominantly Gram -ve ... Microsoft PowerPoint - mcbain to post.ppt [Compatibility Mode] Author:

6/21/2014

14

27

Figure 3 Box plots showing a comparison of L. reuteri tracked by colony morphology (backward diagonals) with major bacterial groups i.e. total anaerobes (white), aerobes (forward diagonals) and total lactobacilli (crossed pattern). The vertical dotted lines enclose period of probiotic treatment. The horizontal bar inside the box represents the median while * indicates significant change observed (p < 0.05).

Total eubacteria

Pre-dosing Dosing Post-dosing

copi

es.m

m-2

2

4

6

8

10

Lactobacillus group qPCR

Pre-dosing Dosing Post-dosing

2

4

6

8

10

Lactobacillus reuteri qPCR

Pre-dosing Dosing Post-dosing

copi

es.

mm

-2

2

4

6

8

10

Persistence of L. reuteri in plaques

Up to three weeks after dosing

28

Direct antagonism?

No inhibition detected against actinomyces, Veillonella dispar, Lactobacillus rhamnosus, Prevotella oralis, Streptococcus mutans, Neisseria subflavaand Streptococcus oralis.

Even at glycerol concentrations of 200mM both Lactobacillus reuteri strains L1 and L2 did not produce any zones of inhibition.

Page 15: mcbain to post.ppt · microflora Facultative anaerobes (Streprococci Actinomycetes etc. Predominantly Gram -ve ... Microsoft PowerPoint - mcbain to post.ppt [Compatibility Mode] Author:

6/21/2014

15

29

Conclusions

• Oral biofilms- taxonomically complex but relatively culturable.

• Specific pathogens implicated in disease but also, considerable functional redundancy in the oral microbiome

• Physical cleaning and antimicrobial- based control regimes remain the clinically proven option.

• Considerable interest in probiotics which are currently (perhaps counter-intuitively) dominated by organisms of intestinal origin. More good quality clinical trials are needed. Mechanisms poorly understood. Considerable potential.